Manufacturers report positive data for nivolumab with relatlimab for melanoma

Top-line data from the RELATIVITY-047 trial for nivolumab, together with the investigational anti-LAG-3 antibody relatlimab in previously untreated metastatic or unresectable melanoma found that the combination met the primary endpoint of improved progression-free survival.

Source:

PharmaTimes